Table 1.
Baseline characteristics of the study patients, according to treatment group.
| Characteristics | Cisplatin-radiotherapy and triapine (N = 13) | Cisplatin-radiotherapy (N = 13) |
|---|---|---|
| Female sex—no. (%) | 13 (100) | 13 (100) |
| Age—year | ||
| Median | 50 | 55 |
| Range | 29–70 | 29–64 |
| Race—no. (%)* | ||
| White | 8 (62) | 11 (85) |
| Black or African ancestry | 1 (8) | 1 (8) |
| Asian | 2 (16) | 0 |
| American Indian or Alaska Native | 1 (8) | 1 (8) |
| Native Hawaiian or Other Pacific Islander | 1 (8) | 0 |
| Ethnicity—no. (%)* | ||
| Not Hispanic or Latina | 11 (85) | 13 (100) |
| Hispanic or Latina | 2 (16) | 0 |
| GOG performance status—no. (%)† | ||
| 0 | 13 (100) | 12 (92) |
| 1 | 0 | 1 (8) |
| 2 | 0 | 0 |
| Disease stage | ||
| IB2 | 2 (16) | 4 (31) |
| IIA | 3 (23) | 1 (8) |
| IIB | 6 (46) | 6 (46) |
| IIIA | 0 | 0 |
| IIIB | 2 (16) | 1 (8) |
| IVA | 0 | 1 (8) |
| Disease histopathology | ||
| Squamous cell carcinoma | 8 (62) | 11 (85) |
| Adenocarcinoma | 3 (23) | 0 |
| Adenosqamous cell carcinoma | 0 | 0 |
| Vaginal squamous cell carcinoma | 2 (16) | 2 (16) |
*
Race and Ethnicity were self-reported.
†
The Gynecologic Oncology Group (GOG) performance status reflects the daily-living abilities of the patient, on a scale of 0 (fully active without symptoms) to 5 (dead).